These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 16114180)
1. Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study. Braga LB; Ferreira AC; Guimarães M; Nazário C; Pacheco P; Miranda A; Picanço I; Seixas T; Rosado L; Amaral JM Hemoglobin; 2005; 29(3):171-80. PubMed ID: 16114180 [TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148 [TBL] [Abstract][Full Text] [Related]
3. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586 [TBL] [Abstract][Full Text] [Related]
4. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience. Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012 [TBL] [Abstract][Full Text] [Related]
5. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992 [TBL] [Abstract][Full Text] [Related]
6. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Al-Nood HA; Al-Khawlani MM; Al-Akwa A Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877 [TBL] [Abstract][Full Text] [Related]
7. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679 [TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia. Al-Jam'a AH; Al-Dabbous IA Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415 [TBL] [Abstract][Full Text] [Related]
9. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439 [TBL] [Abstract][Full Text] [Related]
10. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897 [TBL] [Abstract][Full Text] [Related]
11. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220 [TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813 [TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE; N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550 [TBL] [Abstract][Full Text] [Related]
14. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective. Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171 [TBL] [Abstract][Full Text] [Related]
15. [Sickle cell anemia in children: value of hydroxyurea in severe forms]. Oury AP; Hoyoux C; Dresse MF; Chantraine JM Arch Pediatr; 1997 Sep; 4(9):839-44. PubMed ID: 9345564 [TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy in children severely affected with sickle cell disease. Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience. Jain DL; Apte M; Colah R; Sarathi V; Desai S; Gokhale A; Bhandarwar A; Jain HL; Ghosh K Indian Pediatr; 2013 Oct; 50(10):929-33. PubMed ID: 23798623 [TBL] [Abstract][Full Text] [Related]
18. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922 [TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea in the treatment of sickle-cell anemia. Howard LW; Kennedy LD Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697 [TBL] [Abstract][Full Text] [Related]
20. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers. Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]